Hypothesis

In aging Leydig cells, the StAR protein is deliberately sequestered into insoluble aggregates as a proteostatic safeguard that limits steroidogenesis and thereby reduces mitochondrial ROS production. This adaptive aggregation represents a last‑resort order‑forming response rather than a simple loss‑of‑function defect, and therapeutic dissolution of these aggregates would exacerbate oxidative stress and accelerate Leydig cell senescence.

Rationale

1. Protective aggregation is a conserved stress response – Sequestrase chaperones (Btn2, Hsp42) triage oxidatively damaged proteins into deposition sites that lower cytosolic toxicity [1]. Large insoluble aggregates correlate inversely with oxidative stress, whereas diffuse small aggregates are more harmful [2].
2. LLPS mediates reversible sequestration – Protein aggregates form via liquid‑liquid phase separation, creating compartments that shield misfolded species while preserving the potential for refolding or degradation [3]. Regulated exposure of unstructured domains enables stress‑dependent clustering without permanent loss of function [4].
3. StAR is aggregation‑prone under oxidative conditions – The StAR protein contains a predicted low‑complexity domain and multiple cysteine residues susceptible to disulfide‑linked cross‑linking, making it a candidate for LLPS‑driven deposition when mitochondrial ROS rise in aging Leydig cells.
4. Aggregation limits steroidogenic flux – Sequestered StAR cannot transport cholesterol into mitochondria, directly curbing pregnenolone synthesis and downstream testosterone output. This reduces electron leakage from cytochrome P450scc, a major source of Leydig‑cell ROS.
5. Loss‑of‑function emerges only when clearance fails – With advancing age, lysosomal degradation, ER stress, and UPS decline impede aggregate turnover [5], shifting the balance from protective sequestration to pathogenic accumulation and functional depletion of StAR.

Novel Mechanistic Insight

We propose that the cell actively exploits StAR’s intrinsic disorder to create a ROS‑buffering depot. By sequestering StAR into LLPS‑derived aggregates, the cell:

• Buffers oxidized cholesterol – Aggregates may also capture oxidized sterols that would otherwise propagate lipid peroxidation.
• Tunes mitochondrial substrate supply – Limiting cholesterol import reduces NADH/FADH2 production, attenuating electron‑transport‑chain overload.
• Signals via aggregate‑associated kinases – Scaffolded kinases (e.g., p38 MAPK) could be recruited to the deposit, linking aggregate size to downstream senescence‑associated secretory phenotype (SASP) modulation.

Thus, age‑related testosterone decline is not merely a consequence of StAR degradation but a regulated, protective down‑shift in steroidogenic output that becomes maladaptive only when aggregate clearance collapses.

Testable Predictions

1. Aggregate detection – Aged Leydig cells (human or rodent) will show increased StAR co‑localization with LLPS markers (e.g., FUS, DDX4) and insoluble‑fraction enrichment compared with young cells [2].
2. ROS correlation – StAR aggregate burden will inversely correlate with mitochondrial ROS (MitoSOX) and lipid‑peroxidation (4‑HNE) levels across individual cells.
3. Functional rescue via disaggregase – Overexpression of the Hsp110‑Hsp70‑Hsp40 disaggregase complex or treatment with LLPS‑modulating small molecules (e.g., 1,6‑hexanediol) will reduce StAR aggregates, increase steroidogenic flux, and elevate ROS and DNA‑damage markers (γH2AX) [6].
4. Physiological outcome – Chronic LLPS inhibition in vivo will raise serum testosterone but accelerate Leydig‑cell senescence markers (p16^INK4a^, SA‑β‑gal) and testicular fibrosis.
5. Loss‑of‑function threshold – Genetic ablation of autophagy‑lysosomal pathways (e.g., Atg7 knockdown) will shift StAR from soluble to insoluble states, precipitating a sharp drop in testosterone coincident with heightened oxidative stress.

Falsifiability

If experimentally reducing StAR aggregates does not increase ROS or senescence markers, or if testosterone elevation occurs without aggravating oxidative stress, the protective‑sequestration model would be refuted. Conversely, demonstrating that aggregate removal worsens Leydig‑cell health while preserving or boosting testosterone would strongly support the hypothesis.

Conclusion

Reframing age‑linked StAR aggregation as a deliberate, ROS‑mitigating strategy shifts the therapeutic paradigm from simply dissolving aggregates to modulating their dynamics—preserving the protective depot while enhancing clearance when it becomes detrimental.